Activity in this selectionMay 31, 2026 · May 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- —
2 roles undisclosed- New companies
- 2
First participation on record · 0 follow-on- Funding in participating rounds
- $33.2M
2 disclosed · full round size, not this investor’s share
Rounds
2 in this selectionBlank BioTrains RNA foundation models on tumor transcriptomes to improve patient-level prediction in oncology
Role not disclosed9amHealthAI-enabled virtual specialty care platform for managing high-cost chronic conditions
Role not disclosed